Recent Updates — GIFLF

The Board of Directors approved an interim dividend of €0.15 per share on account of the 2026 profit, with payment scheduled for December 4, 2026. Grifols operates in the plasma-derived biopharmaceutical industry.

Grifols reported third-quarter 2026 revenue of EUR 2,040 million, an increase of 8.4% at constant currency, driven by strong growth in its Biopharma segment. Net profit rose 27.9% to EUR 162 million, while adjusted EBITDA grew 9.8% to EUR 538 million with a margin of 26.4%. Free cash flow pre-M&A reached EUR 208 million in the quarter, bringing year-to-date free cash flow to EUR 298 million. The company confirmed its full-year 2026 guidance and announced an interim dividend of €0.15 per share. Grifols is a global healthcare company and leading producer of plasma-derived medicines.

Grifols announced that its Board of Directors accepted the resignation of Mr. Iñigo Sánchez-Asiaín Mardones from his roles as independent director, Chairperson of the Audit Committee, and member of the Strategy Committee, effective July 29, 2026. To fill the resulting vacancy, the Board appointed Ms. Joanna Susan Le Couilliard as a new independent director and Chairperson of the Audit Committee, leveraging her background in natural sciences and healthcare management. Additionally, Ms. Montserrat Muñoz Abellana was appointed to the Strategy Committee. Grifols operates in the biopharmaceutical industry, specializing in plasma-derived therapies and diagnostics.